A5059144188- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Cancer therapeutics and mechanisms
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- Immunotherapy and Immune Responses
- RNA modifications and cancer
- PI3K/AKT/mTOR signaling in cancer
- Cytokine Signaling Pathways and Interactions
- Pancreatic and Hepatic Oncology Research
- Cancer Treatment and Pharmacology
- Neuroendocrine Tumor Research Advances
- Gastric Cancer Management and Outcomes
- DNA Repair Mechanisms
- Melanoma and MAPK Pathways
- Chemotherapy-related skin toxicity
- HER2/EGFR in Cancer Research
- Cancer-related molecular mechanisms research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- CAR-T cell therapy research
- Cancer Cells and Metastasis
- Peptidase Inhibition and Analysis
- Cancer Mechanisms and Therapy
University of Messina
2016-2025
Istituto Ortopedico Gaetano Pini
2017-2023
Azienda Ospedaliera Universitaria Policlinico "G. Martino"
2017-2021
European Institute of Oncology
2007-2018
Institut Català d'Oncologia
2006-2017
Instituto Oncológico Dr. Rosell
2015-2017
University of Verona
2015-2017
Clínica Santa María
2017
Shanghai Pulmonary Hospital
2017
Tongji University
2017
The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR-mutant non–small cell lung cancer (NSCLC) is limited by adaptive activation survival signals. We hypothesized that both signal transducer and activator transcription 3 (STAT3) Src-YES-associated protein 1 (YAP1) signaling are dually activated during EGFR TKI treatment to limit therapeutic response. used MTT clonogenic assays, immunoblotting, quantitative polymerase chain reaction evaluate the...
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths worldwide. The majority patients are diagnosed in advanced disease stage. Bone metastasis is most frequent complication NSCLC resulting osteolytic lesions. perfect balance between bone-resorbing osteoclasts and bone-forming osteoblasts activity lost bone metastasis, inducing osteoclastogenesis. In NSCLC, epidermal growth factor receptor (EGFR) pathway constitutively activated. EGFR binds Amphiregulin (AREG)...
Osimertinib has confirmed effectiveness in this real-world population of patients with EGFR-mutant advanced non-small cell lung cancer. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients at least three metastatic sites, brain metastases, and symptoms diagnosis seem to have worse prognosis.Osimertinib became the standard treatment for untreated cancer (aNSCLC) following results reported phase...
Immune checkpoints inhibitors (ICIs) have markedly improved the therapeutic management of advanced NSCLC and, more recently, they demonstrated efficacy also in early-stage disease. Despite better survival outcomes with ICIs compared to standard chemotherapy, a large proportion patients can derive limited clinical benefit from these agents. So far, few predictive biomarkers, including programmed death-ligand 1 (PD-L1), been introduced practice. Therefore, there is an urgent need identify...
Abstract BIM is a proapoptotic protein that initiates apoptosis triggered by EGFR tyrosine kinase inhibitors (TKI). mTOR negatively regulates and may influence response to TKI. We examined mRNA expression of MTOR in 57 patients with -mutant NSCLC from the EURTAC trial. Risk mortality disease progression was lower high compared low/intermediate levels. Analysis further divided into two groups, those having both experiencing shorter overall progression-free survival erlotinib. Validation our...
The development of metastasis is the primary cause death in patients with non-small cell lung cancer (NSCLC). However, identifying those NSCLC who will have loco-regional or distant disease recurrence after surgery still challenging. Circulating tumor cells (CTCs) can accurately reflect impact micro-metastasis circulating blood on patients' treatment and prognosis. aim present study was to explore value preoperative CTC concentration predicting postoperative risk NSCLC. This enrolled 347...
To explore the prescription patterns of erythropoiesis-stimulating agents (ESAs) in four large Italian geographic areas, where different health policy interventions to promote biosimilar use routine care are undertaken.A retrospective drug utilization study was conducted during years 2009-2013. The data sources were administrative databases Tuscany region and Caserta, Palermo, Treviso Local Health Units (LHUs). characteristics, prevalence, switching ESAs (biosimilars reference products),...
BackgroundThe activation of multiple signaling pathways jeopardizes the clinical efficacy EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutation positive non-small cell lung cancer (NSCLC). Integrin-linked (ILK) regulates interactions between tumor cells and extracellular environment to activate promote proliferation, migration, epithelial-mesenchymal transition. Src homology 2 domain-containing phosphatase (SHP2) is essential for receptor mitogen-activated protein (MAPK) pathway...